Colon and smooth muscle

The **colon smooth muscle** expresses a range of pharmacologically relevant molecular targets, most notably muscarinic acetylcholine receptors (especially subtypes M2 and M3), which mediate acetylcholine-induced contraction essential for colonic motility[1][2]. These receptors are G protein-coupled and activate intracellular calcium signaling pathways. L-type and T-type calcium channels (voltage-gated ion channels) further regulate smooth muscle contractility by modulating calcium influx, which is essential for muscle contraction. Prostaglandin E2 receptor EP1—also a G protein-coupled receptor—can directly induce contraction in human colon muscle in response to prostanoids such as PGE2[3]. Drugs such as antimuscarinics and calcium channel blockers exploit these targets for the treatment of conditions characterized by excessive colonic motility and spasm, such as irritable bowel syndrome[1][2][3]. Colon and smooth muscle is not a proper name for a molecular target. For structured data and drug discovery, refer to recognized molecular targets: muscarinic receptor subtypes (M2, M3), calcium channels (L-type, T-type), and EP1 receptor for colonic smooth muscle pharmacology[1][2][3].

Other names

Mr2CHRM2Mr3CHRM3CaV1.2LTCCCaV3.1CaV3.2CaV3.3PTGER1

Muscarinic antagonists block acetylcholine-induced contraction; calcium channel blockers inhibit calcium influx and suppress smooth muscle contractility; EP1 antagonists prevent prostanoid-induced contraction.